Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23136944 | 1.00 | TDP1 (0.50) | TDP1GLAALOX15CACNA1HEPHX1 | |
| SCHEMBL48633 | 0.91 | — | — | |
| SCHEMBL13165688 | 0.91 | TDP1 (0.58) | TDP1GLAALOX15CACNA1HEPHX1 | |
| Hydrochloric Acid SCHEMBL4553435 | 0.89 | — | — | |
| SCHEMBL10106981 | 0.84 | TDP1 (0.52) | TDP1GLAALOX15CACNA1HEPHX1 | |
| SCHEMBL4761476 | 0.83 | TDP1 (0.50) | TDP1GLAALOX15CACNA1HEPHX1 | |
| SCHEMBL4761479 | 0.83 | TDP1 (0.50) | TDP1GLAALOX15CACNA1HEPHX1 | |
| SCHEMBL14438969 | 0.83 | TDP1 (0.50) | TDP1GLAALOX15CACNA1HEPHX1 | |
| SCHEMBL25527588 | 0.83 | TDP1 (0.50) | TDP1GLAALOX15CACNA1HEPHX1 | |
| SCHEMBL5969117 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357908-A4 | ACYL SULFAMIDES FOR TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-6852738-B2 | Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, | MERCK & CO., INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040073037-A1 | Anticholesterol agents; cardiovascular disorders; antiinflammatory agents; peroxisome proliferator activator receptor antagonist | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
| EP-1357908-A2 | ACYL SULFAMIDES FOR TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002060388-A2 | ACYL SULFAMIDES FOR TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073037-A1 | Anticholesterol agents; cardiovascular disorders; antiinflammatory agents; peroxisome proliferator activator receptor antagonist | PPARA, PPARD, PPARG | TDP1 3529/4885GLA 384/4885ALOX15 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.